Market Access: Japan Is Not An Add-On For Medtech Manufacturers
Too risky? Too costly? Global medtech innovators have tended to look at Japan as a market they might graduate to after cracking the US and EU. But Japan has changed in recent years and offers opportunities to medtech companies with products for unmet needs, as long as those firms are willing to commit themselves to understanding the dynamics of the market and its unique aspects.
You may also be interested in...
Japan’s “fast-break scheme” is coming soon and will be the country’s fourth procedure for accelerating the approval of important medical devices.
Fujifilm has successfully transformed its business strategy by expanding away from traditional photographic film and toward new priority business fields – significantly in regenerative medicine. Identifying health care as a key growth area, Fujifilm targets the role of being a comprehensive provider in the fields of prevention, diagnosis and treatment.
Point-of-care/near-patient testing has been “two years away from major breakthrough” for at least two decades, but fast access to data via automation and IT means that progress might change at last. How the tests are paid for remains an issue. The future of POC was the theme of an investor discussion at the first DxPx conference, held during the Medica 2019 event in Germany.